IP Library Granted Patent US 7,795,263
Granted Patent B2
US 7,795,263 · App. 12/169,446 · Granted Sep 14, 2010

Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals

Assignee: Wildlife Laboratories, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,795,263
App. No.
12/169,446
Granted
Sep 14, 2010
Kind
B2
Abstract

Non-domesticated mammalian animals are anesthetized and immobilized by injecting an effective amount of an anesthetizing and immobilizing drug comprising pharmaceutically active ingredients of butorphanol tartrate, azaperone tartrate and medetomidine hydrochloride (BAM) into the animal from a dart. The BAM combination is preferably initially formed as lyophilized powder of the pharmaceutically active ingredients, and then reconstituted before injection as an injectable liquid in the environment of the animal.

Claims (16)

1. A pharmaceutical combination capable of reversibly anesthetizing and immobilizing free-ranging non-domesticated mammalian animals, consisting essentially of butorphanol tartrate, azaperone tartrate and medetomidine hydrochloride combined in solution for a single intramuscular injection having a relative weight ratio relationship of 14-55 mg/ml of butorphanol tartrate and 9-36 mg/ml of azaperone tartrate and 5-22 mg/ml of medetomidine hydrochloride.

2. A pharmaceutical combination as defined in claim 1 , wherein the approximate relative weight ratio relationship of the pharmaceutically active ingredients is 27 mg/ml of butorphanol tartrate, 18 mg/ml of azaperone tartrate, and 11 mg/ml of medetomidine hydrochloride.

3. A pharmaceutical combination as defined in claim 1 , wherein the injectable volume of the solution is no more than 3 milliliters.

4. A pharmaceutical combination as defined in claim 1 , wherein the butorphanol tartrate, azaperone tartrate and medetomidine hydrochloride are lyophilized as a powder before injection.

5. A pharmaceutical combination as defined in claim 4 , wherein the lyophilized powder is formulated into the injectable solution by the addition of sterile water.

6. A method of making the pharmaceutical combination defined in claim 1 , comprising combining predetermined quantities of solutions of the butorphanol tartrate, the azaperone tartrate and the medetomidine hydrochloride.

7. A method as defined in claim 6 , further comprising lyophilizing the butorphanol tartrate, the azaperone tartrate and the medetomidine hydrochloride from the solutions to form a powder.

8. A method as defined in claim 6 , wherein the approximate relative weight ratio relationship is 27 mg/ml of butorphanol tartrate, 18 mg/ml of azaperone tartrate, and 11 mg/ml of medetomidine hydrochloride.

9. A method of anesthetizing and immobilizing free-ranging non-domesticated mammalian animals by injecting an effective amount of the pharmaceutical combination defined in claim 1 into the animal from a dart which is projected in a trajectory to the animal.

10. A method as defined in claim 9 , further comprising projecting the dart into the animal in a trajectory of up to 70 meters.

11. A method as defined in claim 9 , further comprising delivering a volume of the pharmaceutical combination to the animal which is no greater than 3 milliliters by the dart.

12. A method as defined in claim 11 , further comprising injecting an animal which has a minimum weight of at least 20 kilograms.

13. A method as defined in claim 9 , wherein an approximate relative weight ratio relationship of the pharmaceutically active ingredients is 27 mg/ml of butorphanol tartrate, 18 mg/ml of azaperone tartrate, and 11 mg/ml of medetomidine hydrochloride.

14. A method as defined in claim 9 , further comprising constituting the solution from a lyophilized powder of butorphanol tartrate, azaperone tartrate and medetomidine hydrochloride by adding sterile water to the powder.

15. A method as defined in claim 14 , further comprising adding the sterile water to the powder in the environment in which the animal is present before injecting the animal.

16. A method as defined in claim 9 , further comprising substantially reversing the anesthesia and immobilization by injecting the animal with antagonists of the butorphanol tartrate and the medetomidine hydrochloride.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Dec 24, 2025
From: NATIXIS, NEW YORK BRANCH
To: WEDGEWOOD PHARMACY, LLC (F/K/A WEDGEWOOD VILLAGE PHARMACY, LLC); WILDLIFE LABORATORIES, LLC
Reel/Frame 073309/0637 →
RELEASE OF SECURITY INTEREST Recorded Dec 24, 2025
From: NATIXIS, NEW YORK BRANCH
To: WEDGEWOOD PHARMACY, LLC (F/K/A WEDGEWOOD VILLAGE PHARMACY, LLC); WILDLIFE LABORATORIES, LLC
Reel/Frame 073309/0617 →
SECURITY INTEREST Recorded Dec 23, 2025
From: WILDLIFE LABORATORIES, LLC; WEDGEWOOD PHARMACY LLC; SR VETERINARY TECHNOLOGIES, LLC
To: TCG SENIOR FUNDING, L.L.C.
Reel/Frame 073307/0883 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS RECORDED AT R/F 055804/0377 Recorded Jul 8, 2025
From: MACQUARIE CAPITAL FUNDING LLC
To: NATIXIS, NEW YORK BRANCH
Reel/Frame 071842/0563 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS RECORDED AT R/F 055804/0396 Recorded Jul 8, 2025
From: MACQUARIE CAPITAL FUNDING LLC
To: NATIXIS, NEW YORK BRANCH
Reel/Frame 071842/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2025
From: WILDLIFE LABORATORIES, LLC
To: SR VETERINARY TECHNOLOGIES, LLC
Reel/Frame 070195/0881 →
RELEASE OF SECURITY INTEREST Recorded Apr 7, 2021
From: MARANON CAPITAL, L.P.
To: WILDLIFE LABORATORIES, LLC
Reel/Frame 055856/0841 →
SECURITY INTEREST Recorded Apr 2, 2021
From: WILDLIFE LABORATORIES, LLC
To: MACQUARIE CAPITAL FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 055804/0377 →
SECURITY INTEREST Recorded Mar 17, 2021
From: WILDLIFE LABORATORIES, LLC
To: MARANON CAPITAL, L.P., AS AGENT
Reel/Frame 055628/0552 →
ENTITY CONVERSION AND CHANGE OF NAME Recorded Nov 20, 2020
From: WILDLIFE LABORATORIES, INCORPORATED
To: WILDLIFE LABORATORIES, LLC
Reel/Frame 054485/0385 →
CORRECTIVE ASSIGNMENT TO CORRECT THE EXECUTION DATE PREVIOUSLY RECORDED ON REEL 049474 FRAME 0513. ASSIGNOR(S) HEREBY CONFIRMS THE NATURE OF CONVEYANCE AS SECURITY INTEREST. Recorded Jul 2, 2019
From: WILDLIFE LABORATORIES, INC.
To: GREAT WESTERN BANK
Reel/Frame 049649/0554 →
RELEASE OF SECURITY INTEREST Recorded Jun 21, 2019
From: GREAT WESTERN BANK
To: WILDLIFE EQUITIES, INC.
Reel/Frame 049551/0091 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED AT REEL: 027836 FRAME: 0348. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Jun 14, 2019
From: WILDLIFE LABORATORIES, INC.
To: GREAT WESTERN BANK
Reel/Frame 049474/0513 →
SECURITY INTEREST Recorded Mar 9, 2012
From: WILDLIFE LABORATORIES, INC
To: GREAT WESTERN BANK
Reel/Frame 027836/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2008
From: LANCE, WILLIAM R.; WOLFE, LISA L.
To: WILDLIFE LABORATORIES, INC.
Reel/Frame 021208/0481 →
Continuity (1)
Related Publication 20100010006A1 · Jan 14, 2010